Acrylic Acid And Derivatives Patents (Class 424/487)
-
Patent number: 9161914Abstract: The present invention relates to improved topical gel compositions comprising an active agent, and uses thereof.Type: GrantFiled: June 5, 2014Date of Patent: October 20, 2015Assignee: Merz Pharmaceuticals, LLCInventors: Bhushan Hardas, Donna Dalton
-
Patent number: 9056137Abstract: The present invention provides thermo-sensitive, mucoadhesive biopolymer formulations that enhance the penetration of therapeutics across the skin or mucosal surfaces. In a preferred embodiment, the biopolymer formulation comprises co-polymer of poloxamer 188 and propylene glycol, laurocapram and, optionally, one or more therapeutic agents. Also provided are uses of the biopolymer formulations for topical therapy of cancer including cervical cancer.Type: GrantFiled: March 29, 2012Date of Patent: June 16, 2015Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATEDInventor: Stephen I-Hong Hsu
-
Patent number: 9023382Abstract: A medicament carrier composition includes a medicament and a polymer component including a polyvinylpyrrolidone having a weight average molecular weight of at least 700,000 g/mol. The medicament carrier composition has a viscosity of from 500 to 5,000 cps at 250 C, is substantially free of cellulose, and includes an auxiliary polymer. The medicament carrier composition is used to form a film that is also substantially free of cellulose. The film has a consistent thickness and size, and an increased flexibility and increased moisture resistance due to the polyvinylpyrrolidone. The medicament carrier composition is also used in a method of forming the film. The method includes the steps of providing the medicament and the polymer component. The method also includes the step of combining the polymer component and the medicament to form the medicament carrier composition. The method further includes the step of drying the medicament carrier composition to form the film.Type: GrantFiled: April 24, 2006Date of Patent: May 5, 2015Assignee: BASF CorporationInventors: Shaukat Ali, Anisul Quadir
-
Patent number: 9017723Abstract: Propynylaminoindan (e.g., Rasagiline) transdermal compositions are provided. Aspects of the transdermal compositions include a matrix of the propynylaminoindan in a pressure sensitive adhesive comprising a carboxylated polymer. In some instances, the matrix further includes a cationic acrylic copolymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.Type: GrantFiled: March 21, 2011Date of Patent: April 28, 2015Assignee: Teikoku Pharma USA, Inc.Inventors: Jianye Wen, Richard Hamlin
-
Patent number: 9012424Abstract: The present invention relates to a polymer according to Formulas (1) or (2): The present invention further relates to nanogels and nanoparticles made of a polymer according to general Formulas (1) and (2). The nanogels may comprise a biologically active component such as siRNA, miRNA, DNA, an (oligo)peptide or a proteins.Type: GrantFiled: May 25, 2012Date of Patent: April 21, 2015Assignee: 20MED Therapeutics B.V.Inventors: Johannes Franciscus Joseph Engbersen, Arkadi Vladimirovich Zinchenko
-
Publication number: 20150098997Abstract: Aspects of the invention include methods of treating ADHD, anxiety or insomnia by applying a transdermal delivery device containing a dexmedetomidine composition formulated to deliver an amount of dexmedetomidine to a subject diagnosed as having ADHD, anxiety or insomnia. In practicing methods according to certain embodiments, a transdermal delivery device having a dexmedetomidine composition is applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver an amount of dexmedetomidine sufficient to treat ADHD, anxiety or insomnia in the subject. Also provided are transdermal delivery devices configured to deliver an amount of dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery devices.Type: ApplicationFiled: October 3, 2014Publication date: April 9, 2015Inventors: Adchara Pongpeerapat, Amit Jain, Bret Berner, Jianye Wen, Jutaro Shudo
-
Patent number: 8992899Abstract: Disclosed herein are cosmetic compositions comprising at least one film-forming polymer, at least one silicone elastomer blend, and at least one wax. Also disclosed herein are methods for making up and/or enhancing the appearance of a keratinous substrate comprising applying said composition to the keratinous substrate.Type: GrantFiled: December 31, 2012Date of Patent: March 31, 2015Assignee: L'OrealInventors: Kavita Patel, Angeles Fonolla-Moreno, Naoto Sugimoto
-
Patent number: 8986735Abstract: A solid dosage form containing a taste masked active agent is provided. The solid dosage form may be provided as a water soluble film that is disintegrable in the oral cavity to deliver and release the taste masked active agent. The disintegrable film includes at least one water soluble polymer and a taste masked ketoprofen active. Also provided are methods for preparing the solid dosage form and for using the solid dosage to administer an effective dosage of an active agent, such as ketoprofen, into the oral cavity for absorption.Type: GrantFiled: March 15, 2007Date of Patent: March 24, 2015Assignee: Novartis AGInventors: Alexander M Schobel, Shyam S Vangala
-
Patent number: 8968783Abstract: The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with both denser and less dense regions.Type: GrantFiled: May 24, 2011Date of Patent: March 3, 2015Assignee: Covidien LPInventors: Steven Bennett, Nathaniel Mast, Kevin Lavigne, Walter Skalla
-
Patent number: 8957008Abstract: Agent for obtaining a stable aqueous composition comprising an association: of a polymer constituted by: at least one A monomer of acrylic acid and/or methacrylic acid and/or any of their salts, at least one B monomer of alkyl acrylate and/or methacrylate, and At least one crosslinking D monomer, and with at least one C compound corresponding to the following formulae (I): R1-O-[(EO)n(PO)n?(BO)n?]—Z??(I) in which: R1 represents an ethyl, isopropyl or sec-butyl radical, [(EO)n(PO)n?(BO)n?] represents a polyalkoxylated chain constituted of alkoxylated units, distributed into blocks, alternatively or statistically, chosen from among EO ethoxylated units, PO propoxylated units and BO butoxylated units, representing, independently from each other, 0 or a whole number between 1 and 150, the sum of n, n? and n? not being null, and Z represents a fatty chain, linear or branched, of at least 16 carbon atoms.Type: GrantFiled: December 19, 2013Date of Patent: February 17, 2015Assignee: CoatexInventors: Renaud Souzy, Yves Kensicher, Olivier Guerret
-
Patent number: 8940318Abstract: Disclosed is a sustainedly drug-releasing hydrogel contact lens which can sustainedly release an anionic medicament such as an allergy-treating agent in a mildly irritating and effective manner while achieving vision correction. Specifically disclosed is a hydrogel comprising ionic monomers composed of at least a cationic monomer and an anionic monomer, wherein the component ratio of the ionic monomers is 5 to 20 mol % inclusive relative to the total amount of monomers that constitute the gel, and the content of the anionic monomer is 15 to 25 mol % inclusive relative to the content of the cationic monomer.Type: GrantFiled: January 15, 2010Date of Patent: January 27, 2015Assignees: Seed Co., Ltd., Senju Pharmaceutical Co., Ltd.Inventors: Takao Sato, Toru Matsunaga, Aya Ichinokawa, Osamu Sakai
-
Patent number: 8927023Abstract: The invention relates to a biocompatible, non-biodegradable, and non-toxic polymer of formula (I), comprising of three monomeric units, selected from 1-Vinylpyrrolidne (VP), N-Isopropylactylamide (NIPAM), and ester of Maleic anhydride and Polyethylene glycol (MPEG), cross-linked with a bi-functional vinyl derivative, of high purity and substantially free of respective toxic monomeric contaminants, and a process for preparation thereof. The invention further relates to nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds comprising the polymer of the invention, which are safe, less-toxic and convenient for bedside administration to patients in need thereof. Furthermore, the invention relates to a highly selective method for preparation of nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds.Type: GrantFiled: October 2, 2012Date of Patent: January 6, 2015Assignee: Fresenius Kabi Oncology LimitedInventors: Anand C. Burman, Rama Mukherjee, Dhiraj Khattar, Sanjoy Mullick, Manu Jaggi, Manoj Kumar Singh, Mukesh Kumar, Deepak Prusthy, Pawan Kumar Gupta, Rajendran Praveen, Shobhit Singh
-
Patent number: 8916683Abstract: Described herein are block copolymer conjugates that form double-network hydrogels under appropriate conditions. The conjugates comprise a block of polymer end-group, a block of self-associating peptide or protein, and flexible linkers between the two. Hydrogels comprising the conjugates have the mechanical properties, including elastic modulus and fracture toughness, required for load-bearing applications, while maintaining desirable shear-thinning properties, for example, for injectability.Type: GrantFiled: October 5, 2011Date of Patent: December 23, 2014Assignee: Massachusetts Institute of TechnologyInventors: Bradley D. Olsen, Matthew J. Glassman, Jacqueline Chan
-
Patent number: 8907153Abstract: The present invention is drawn to adhesive peel-forming formulations for dermal delivery of a drug. The formulation can include a drug, a solvent vehicle, and a peel-forming agent. The solvent vehicle can include a volatile solvent system having one or more volatile solvent, and a non-volatile solvent system having one or more non-volatile solvent, wherein the non-volatile solvent system has a solubility for the drug that is within a window of operable solubility for the drug such that the drug can be delivered at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified peelable layer after at least a portion of the volatile solvent system is evaporated.Type: GrantFiled: June 6, 2005Date of Patent: December 9, 2014Assignee: Nuvo Research Inc.Inventors: Jie Zhang, Kevin S. Warner, Michael A. Ashburn, Larry D. Rigby, Suyi Niu
-
Patent number: 8883212Abstract: The invention provides novel dental film-forming compositions, comprising i. an acrylate/octylacrylamide copolymer, ii. one or more alkyl cellulose ethers, and iii. a solvent, and optionally further comprising whitening materials and/or active agents, together with method for using the same.Type: GrantFiled: November 7, 2011Date of Patent: November 11, 2014Assignee: Colgate-Palmolive CompanyInventors: Shyamala Pillai, Guofeng Xu
-
Patent number: 8871245Abstract: A transdermal patch for the treatment of Alzheimer's disease includes: a backing, a rivastigmine-containing layer, a pressure-sensitive adhesive layer, and a release liner. In the transdermal patch, the rivastigmine-containing layer contains rivastigmine and an alkyl (meth)acrylate resin, the pressure-sensitive adhesive layer is composed of an acrylic pressure-sensitive adhesive containing a (meth)acrylic acid ester having a hydroxy group, and neither the rivastigmine-containing layer nor the pressure-sensitive adhesive layer contains an anti-oxidizing agent.Type: GrantFiled: February 28, 2012Date of Patent: October 28, 2014Assignee: Nichiban Co., Ltd.Inventors: Takao Hiraoka, Shuta Nakanami, Toru Koga
-
Gastrointestinal absorption enhancer mediated by proton-coupled transporter and its preparing method
Patent number: 8871818Abstract: The present invention provides a pharmaceutical preparation that can improve absorption of a pharmaceutical compound in the gastrointestinal tract and that provides, through oral administration or like method, a blood concentration from which sufficient remedial effects can be expected, and a method for producing such a preparation. The invention is directed to a pharmaceutical preparation exhibiting excellent gastrointestinal absorbability comprising a compound recognized by a proton-coupled transporter and a pH-sensitive polymer in an amount sufficient for the gastrointestinal tract to acquire a pH at which the proton-coupled transporter optimally absorbs the compound into a cell.Type: GrantFiled: October 21, 2008Date of Patent: October 28, 2014Assignees: Otsuka Pharmaceutical Co., Ltd.Inventors: Akira Tsuji, Ikumi Tamai, Yoshimichi Sai, Masaaki Odomi, Hidekazu Toyobuku -
Patent number: 8871268Abstract: Methods of manufacturing a three-dimensional, biodegradable, thermoset polymeric network composition having desirable degradation and mechanical properties, comprising a macromer component cross-linked with a monofunctional acrylate-containing component. The macromer component can comprise a diacrylate-containing component polymerized with an amine-containing component, wherein the molar ratio of the diacrylate-containing component to the amine-containing component is greater than or equal to 1.Type: GrantFiled: February 23, 2011Date of Patent: October 28, 2014Assignees: Georgia Tech Research Corporation, Emory UniversityInventors: David Safranski, Kenneth Gall, W. Robert Taylor, Daiana Weiss
-
Patent number: 8871512Abstract: Sugar-acrylic monomers are synthesized to have a carbohydrate moiety linked to an acrylate group. The sugar-acrylic monomers may be polymerized to form polymers, adhesives, hydrogels, and the like. The sugar-acrylic monomers and polymers may be used in tissue engineering, adhesives and sealers, wound healing, and the like.Type: GrantFiled: October 27, 2010Date of Patent: October 28, 2014Assignee: Empire Technology Development LLCInventors: William B. Carlson, Gregory D. Phelan, Phillip A. Sullivan
-
Patent number: 8865201Abstract: A hydrophilic matrix is disclosed which comprises: a) at least one polyacrylic acid derivative in preferred amounts of 0.5-40%, b) at least one cellulose ether in preferred amounts of 30-90% and c) at least one disintegrant in preferred amounts of 2-50%, with respect to the weight of the matrix. This matrix is used in combination with at least one pharmaceutically acceptable active principle for manufacturing solid bioadhesive controlled release formulations for the treatment of vaginal disorders, such as vulvovaginal candidiasis, bacterial vaginosis or trichomoniasis. According to a preferred embodiment, the matrix is used in amounts of about 5-60% and the active principle in amounts of about 2-70%, with respect to the weight of the formulation.Type: GrantFiled: June 21, 2007Date of Patent: October 21, 2014Assignee: Polichem SAInventors: Stefano De Luigi Bruschi, Federico Mailland
-
Patent number: 8865792Abstract: This invention relates to medicine, more specifically, to surgical devices, and can be used for gluing soft body tissues. The medical glue comprises 3-methacryloxysulpholane, N-butyl-2-cyanoacrylate and at least one stabilizer.Type: GrantFiled: February 6, 2012Date of Patent: October 21, 2014Inventor: Gennady Leplianin
-
Publication number: 20140294960Abstract: Implantable modular hydrogels to aid in salivary gland restoration and associated methods are provided. In one embodiment, the present disclosure provides for a hydrogel network comprising: a hyaluronic acid macromer crosslinked with a multiblock copolymer.Type: ApplicationFiled: June 16, 2014Publication date: October 2, 2014Inventors: Robert L. Witt, Xinqiao Jia, Swati Pradham Bhatt, Mary C. Farach-Carson, Daniel A. Harrington
-
Publication number: 20140294953Abstract: The disclosure relates to a sustained-release oral dosage form for once-a-day administration comprising a matrix containing a viscosity modifier and coated granules containing hydromorphone. The dosage form can have a release profile such that 16 hours following administration, less than about 85 percent of the hydromorphone is released. In addition, the dosage form may have alcohol and/or crush resistance.Type: ApplicationFiled: June 5, 2014Publication date: October 2, 2014Inventors: Ehab Hamed, Manuel A. Vega Zepeda
-
Patent number: 8846093Abstract: Transdermal drug delivery patches and methods of their production are described. The patches can be made such that the accommodate highly plasticizing drugs such as selegiline and/or the use of protonated forms of various drugs.Type: GrantFiled: May 4, 2011Date of Patent: September 30, 2014Assignee: Mylan Technologies, Inc.Inventors: Sharad K. Govil, Ludwig J. Weimann
-
Publication number: 20140271866Abstract: The present invention provides a transdermal drug delivery system comprising rivastigmine or its pharmaceutically acceptable salt and method of making the same.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: NAL PHARMACEUTICALS, LTD.Inventor: Je Phil Ryoo
-
Publication number: 20140271865Abstract: Described are transdermal drug delivery compositions comprising amphetamine, methods of making them and therapeutic methods using them. The compositions are provided in a flexible, finite form (e.g. “patch”-type systems) and comprise a polymer matrix that includes amphetamine and an acrylic block copolymer.Type: ApplicationFiled: March 12, 2014Publication date: September 18, 2014Applicant: NOVEN PHARMACEUTICALS, INC.Inventors: Robert Lambert, Weijun Lu, Jun Liao
-
Patent number: 8828358Abstract: A composition for in situ formation of an artificial blockage to control bleeding includes a suitable amount of a polymer-forming component, a suitable amount of a crosslinking agent, hydrogen peroxide, and a decomposing agent for hydrogen peroxide. The decomposing agent includes exogenous or endogenous catalase, or both.Type: GrantFiled: March 11, 2008Date of Patent: September 9, 2014Assignee: Materials Modifications, Inc.Inventors: Joseph G. Montes, Krishnaswamy Kasthuri Rangan, Ramachandran Radhakrishnan, Tirumalai Srinivas Sudarshan
-
Patent number: 8821933Abstract: Methods and compositions related polymers and hydrogels. In some cases to biodegradable hydrogels for use in medical applications are disclosed. The polymers and hydrogels may be produced from cross-linked dextran and poly(epoxides). The poly(epoxides) may be poloxamers.Type: GrantFiled: November 1, 2011Date of Patent: September 2, 2014Assignee: nanoDERM Sciences, Inc.Inventors: Roy R. Yeoman, Adrian S. Fox
-
Patent number: 8821583Abstract: A strain-hardened interpenetrating polymer network (IPN) hydrogel is provided. The interpenetrating polymer network hydrogel is based on two different networks. The first network is a non-silicone network of preformed hydrophilic non-ionic telechelic macromonomers chemically cross-linked by polymerization of its end-groups. The second network is a non-silicone network of ionizable monomers. The second network has been polymerized and chemically cross-linked in the presence of the first network and has formed physical cross-links with the first network. An aqueous salt solution having a neutral pH is used to ionize and swell the second network in the interpenetrating polymer network. The swelling of the second network is constrained by the first network, and this constraining effect results in an increase in effective physical cross-links within the interpenetrating polymer network, and, in turn, an increase its elastic modulus.Type: GrantFiled: February 15, 2008Date of Patent: September 2, 2014Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: David Myung, Laura Hartmann, Jean Noolandi, Christopher N. Ta, Curtis W. Frank
-
Patent number: 8821899Abstract: The present invention includes compositions, methods, systems for the controlled delivery of an active agent within a polymeric network upon the binding of a molecule that decreases the structural integrity of the polymeric network at one or more micro- or nanovacuoles.Type: GrantFiled: December 4, 2008Date of Patent: September 2, 2014Assignee: Board of Regents, The University of Texas SystemInventors: Nicholas A. Peppas, Barbara Ekerdt, Marta Gomez-Burgaz
-
Patent number: 8815283Abstract: An immuno-compatible hydrogel system is provided that is resistant to protein binding. The hydrogel system is prepared by contacting a hydrogel solution with a cross-linking agent to form a gel, exposing the gel to an aqueous solution comprising a first polyelectrolyte to form a polyelectrolyte-coated hydrogel, exposing the polyelectrolyte-coated hydrogel to a second polyelectrolyte to form a crosslinked matrix and exposing the matrix to conditions which eliminates, or at least reduces, protein binding sites on the matrix.Type: GrantFiled: June 2, 2010Date of Patent: August 26, 2014Assignee: McMaster UniversityInventors: Harald Stover, Nicholas Burke, Casey Mills
-
Patent number: 8784892Abstract: The present invention is directed to the use of an agent selected from ethyl alcohol, isopropyl alcohol or a mixture thereof and a topically acceptable polymeric carrier in the preparation of a composition for the treatment of burns.Type: GrantFiled: July 7, 2010Date of Patent: July 22, 2014Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventor: Elka Touitou
-
Patent number: 8785118Abstract: A method for fixing a supercoiled DNA consists in deposing a supercoiled DNA sample on the surface of a porous polymer film, in fixing said supercoiled DNA therein by a passive diffusion, in obtaining a support by the inventive method and in using said support for analyzing the DNA distribution.Type: GrantFiled: June 19, 2006Date of Patent: July 22, 2014Assignee: Commissariat a l'Energie Atomique et Aux Energies AlternativesInventors: Jean-François Millau, Sylvie Sauvaigo
-
Patent number: 8778396Abstract: This invention relates to an orally administrable, gastroretentive pharmaceutical dosage form which contains at least one pharmaceutically active ingredient and at least one polymeric adjuvant. The adjuvant serves to retain the dosage form in a selected region of the gastrointestinal tract for sufficient time for the pharmaceutically active ingredient to be released and absorbed. Ideally the dosage form will contain two or more pharmaceutically active ingredients which are delivered to different regions of the gastrointestinal tract.Type: GrantFiled: June 3, 2009Date of Patent: July 15, 2014Assignee: University of the Witwatersrand, JohannesburgInventors: Viness Pillay, Yahya Choonara, Caragh Murphy, Sarashnee Moonisami
-
Patent number: 8771713Abstract: The present invention includes compositions, methods, systems for the controlled delivery of an active agent in a tablet polymer comprising two or more layers, wherein each of the two or more layers comprises at least one active agent and at least one molecular recognition polymer, wherein the two or more layers are compressed into a single tablet.Type: GrantFiled: March 3, 2009Date of Patent: July 8, 2014Assignee: Board of Regents, The University of Texas SystemInventors: Nicholas A. Peppas, Barbara Ekerdt, Marta Gomez-Burgaz
-
Patent number: 8771739Abstract: The present invention provides a pharmaceutical composition of a practically insoluble drug, wherein the composition may be administered with food or without food. The composition may be in the form of a solid dispersion of the practically insoluble drug and a polymer having acidic functional groups, and the composition may in vitro form a suspension.Type: GrantFiled: June 15, 2007Date of Patent: July 8, 2014Assignee: Mayne Pharma International Pty LtdInventors: David Hayes, Angelo M. Morella
-
Patent number: 8741982Abstract: A bioactive and osteoconductive bone cement is produced from polyacrylates or polymethylacrylates by addition of small amounts of polymerizable monomers containing anionic groups which cause the cement surface to mineralize after being incubated in simulated body fluid. The obtained mineralized layers contain calcium phosphate phases such that the formation of fibrous intermediate layers is prevented once the bone cement has been implanted in bones. Optionally, other additives, e.g. biocompatible calcium salts, biocompatible buffering substances, or x-ray contrast agents, antibiotics, antimicrobial agents, and/or anti-inflammatory agents can be added in order to improve the properties of the cement for individual purposes. The bone cement can be used for anchoring prosthesis components in the bone, stiffening bones, filling and reconstructing all types of bone defects, as dowels for bone screws, or as an implant material for anchoring screws and other implants used for osteosynthesis.Type: GrantFiled: May 9, 2006Date of Patent: June 3, 2014Assignee: InnoTERE GmbHInventor: Berthold Nies
-
Patent number: 8741316Abstract: The present invention includes compositions, methods, systems of making a composition that includes one or more active agent; a recognitive polymeric matrix; and a porosigen, wherein the composition comprises a porous recognitive, swellable hydrogel that dissociates under conditions of low water or humidity.Type: GrantFiled: December 4, 2008Date of Patent: June 3, 2014Assignee: Board of Regents, The University of Texas SystemInventors: Nicholas A. Peppas, Aditya Durgam
-
Patent number: 8741331Abstract: A composition is provided, wherein the composition comprises a water-swellable, water-insoluble polymer, a blend of a hydrophilic polymer with a complementary oligomer capable of hydrogen or electrostatic bonding to the hydrophilic polymer. The composition also includes a backing member. Active ingredients, such as a whitening agent, may be included. The composition finds utility as an oral dressing, for example, a tooth whitening composition that is applied to the teeth in need of whitening. The composition can be designed to be removed when the degree of whitening has been achieved or left in place and allowed to erode entirely. In certain embodiments, the composition is translucent. Methods for preparing and using the compositions are also disclosed.Type: GrantFiled: June 12, 2013Date of Patent: June 3, 2014Assignees: A. V. Topchiev Institute of Petrochemicals Synthesis, Russian Academy of Sciences, Corium International, Inc.Inventors: Parminder Singh, Adrian Faasse, Gary W. Cleary, Sri Mudumba, Mikhail M. Feldstein, Danir F. Bairamov
-
Publication number: 20140127300Abstract: The invention is directed to oral drug dosage forms designed to reduce the abuse potential of an oral dosage form of an opioid analgesic. The oral drug dosage form comprises a first population of drug-resin complex particles comprising an analgesically effective amount of an opioid drug, said first population of particles coated with a water-permeable diffusion barrier coating. The oral drug dosage form further comprises a second population of ion exchange-resin complex particles comprising an aversive agent, said second population of particles coated with a polymer coating sufficient to substantially prevent release of the aversive agent under normal use conditions. The aversive agent is present in an amount effective to partially or substantially deny the drug abuser the euphoric effect and/or cause an aversive effect in the user.Type: ApplicationFiled: July 2, 2012Publication date: May 8, 2014Applicant: Neos Therapeutics, LPInventors: Mark Tengler, Russell McMahen
-
Publication number: 20140127292Abstract: Oral pharmaceutical compositions for the controlled release of heparin or derivatives thereof, for example dalteparin, salts and/or derivatives thereof, comprising (a) a matrix consisting of amphiphilic compounds and lipophilic compounds with melting point lower than 90° C. in which the active ingredient is at least partially dispersed; (b) an outer hydrophilic matrix in which the lipophilic/amphiphilic matrix is dispersed; (c) optionally, other excipients suitable for solid pharmaceutical forms. The treatment of inflammatory bowel diseases (IBD) by administering to a patient in need thereof an effective amount of dalteparin, salts and/or derivatives thereof is also disclosed.Type: ApplicationFiled: December 30, 2013Publication date: May 8, 2014Applicant: Cosmo Technologies LimitedInventors: Mauro Ajani, Luigi Moro, Roberto Villa
-
Publication number: 20140112980Abstract: An abuse-resistant controlled release pharmaceutical composition comprising a pharmaceutically effective amount of discrete particles of an active capable of abuse, wherein surfaces of said particles are wetted with a water insoluble coating material, and preferably wherein said composition comprises a matrix, in which said particles are distributed, and which renders the abuse-capable compound within the matrix difficult to separate from the matrix; and a method for the preparation of a controlled release pharmaceutical composition having a reduced potential for abuse, comprising applying a pressure force to a mixture comprising a water insoluble material, and particles of a pharmaceutically active compound capable of inducing in a subject a reaction that is physiologically or psychologically detrimental if administered in an immediate release dosage form, thereby resulting in surface coated particles, and incorporating said surface coated particles into a pharmaceutical compositionType: ApplicationFiled: December 23, 2013Publication date: April 24, 2014Inventors: Farid Vaghefi, Gary G. Liversidge, Stephen B. Ruddy, Eugene R. Cooper
-
Patent number: 8703171Abstract: The present invention relates to a method of easing childbirth using a composition having a lubricant effect for use in particular during human vaginal delivery. The methods comprise applying a bioadhesive composition comprising (a) a polyacrylic acid, (b) a water-soluble thickener and (c) a humectant and (d) optionally water.Type: GrantFiled: November 10, 2005Date of Patent: April 22, 2014Assignee: HCB Happy Child Birth Holding AGInventor: Andreas F. Schaub
-
Patent number: 8703180Abstract: Disclosed are compositions with sustained-release carriers associated with at least two different types of growth factors and methods of fabrication and treatments thereof. In some embodiments, simultaneous release of the growth factors may be preferred while in other embodiments, sequential release of the growth factors may be preferred. Application of at least two growth factors to an injury site, e.g., compromised cardiac tissue caused by, for example, myocardial infarction or ischemic heart failure, may better mimic and induce the complex growth factor signaling pathways necessary to improve cardiac function. When applied to a patient after a myocardial infarction or ischemic heart failure, multiple growth factors within a sustained-release carrier platform or platforms may cause a synergistic effect on injected cells intending to alleviate left ventricle remodeling. Methods of treatment include percutaneous, sub-xiphoid, and open chest methods using catheters and/or syringes.Type: GrantFiled: October 23, 2007Date of Patent: April 22, 2014Assignee: Abbott Cardiovascular Systems Inc.Inventors: John J. Stankus, Florian N. Ludwig, Evgenia Mandrusov, Liangxuan Zhang, Hong Ma, Jinping Wan, Shubhayu Basu
-
Publication number: 20140105979Abstract: Compositions for the transdermal delivery of methylphenidate in a flexible, finite form are described. The compositions comprise a polymer matrix that includes methylphenidate or a pharmaceutically acceptable salt and at least one acrylic polymer that is non-reactive with methylphenidate. Methods using the compositions to achieve transdermal delivery of methylphenidate or for treating Attention Deficit Disorder (ADD) and/or Attention Deficit/Hyperactivity Disorder (ADHD), postural orthostatic tachycardia syndrome, or narcolepsy also are described.Type: ApplicationFiled: October 11, 2013Publication date: April 17, 2014Applicant: Noven Pharmaceuticals, Inc.Inventors: Jun Liao, Puchun Liu, Steven Dinh
-
Patent number: 8696760Abstract: Biocompatible synthetic or natural scaffolds are provided for the reconstruction, repair, augmentation or replacement of organs or tissue structures in a patient in need of such treatment. The scaffolds are shaped to conform to at least a part of the organ or tissue structure and may be seeded with one or more cell populations. Inserts, receptacles and ports are also provided for the attachment of tubular vessels to the neo-organ scaffolds. The seeded scaffolds are implanted into the patient at the site in need of treatment to form an organized organ or tissue structure. The scaffolds may be used to form organs or tissues, such as bladders, urethras, valves, and blood vessels.Type: GrantFiled: March 1, 2011Date of Patent: April 15, 2014Assignee: Tengion, Inc.Inventors: Timothy A. Bertram, Andrew Bruce, Deepak Jain, Manuel J. Jayo, John W. Ludlow, Darell McCoy, Richard Payne, Namrata D. Sangha, Oluwatoyin A. Knight
-
Patent number: 8697112Abstract: A method for treating a surface with a therapeutic agent is disclosed. The method comprises precipitating a therapeutic agent from a hydrophilic polymeric base layer with which the therapeutic agent has been complexed, to form a layer comprising microparticles of the therapeutic agent on the hydrophilic polymeric base layer, the hydrophilic polymeric base layer being grafted to the surface. Devices comprising a surface having a hydrophilic polymeric base layer comprising a hydrophilic polymer grafted to the surface and a layer comprising microparticles of a therapeutic agent disposed on and complexed with the hydrophilic polymeric base layer are also disclosed.Type: GrantFiled: July 6, 2012Date of Patent: April 15, 2014Assignee: Covalon TechnologiesInventors: Vyacheslav Dudnyk, Valerio DiTizio
-
Patent number: 8691320Abstract: A method for coating a stent can involve a device having a drying zone, a spray zone, and movable member for positioning a stent in the drying zone and another stent in the spray zone. Each stent can be on a support. A force can be applied to the outside surface of a stent to prevent rotation of the stent with respect to the support.Type: GrantFiled: February 28, 2011Date of Patent: April 8, 2014Assignees: Abbott Cardiovascular Systems Inc., ATS Automation Tooling Systems Inc.Inventors: David Rego, Kurt Kilchenmann, Sang joon Park, Mark Haight, Anthony S. Andreacchi, Yung-Ming Chen, Arnoldo M. Currlin, Antonio Garcia, Jason Van Sciver, Thomas David Esbeck, Bryan D. Glenn, Patrick A. Tuohy, Richard Baillargeon, Edward P. Garcia, Steven E. Lehner, Ian Coulson
-
Patent number: 8691203Abstract: The present inventions in various aspects provide elastic biodegradable polymers. In various embodiments, the polymers are formed by the reaction of a multifunctional alcohol or ether and a difunctional or higher order acid to form a pre-polymer, which is cross-linked to form the elastic biodegradable polymer. In preferred embodiments, the cross-linking is performed by functionalization of one or more OR groups on the pre-polymer backbone with vinyl, followed by photopolymerization to form the elastic biodegradable polymer composition or material. Preferably, acrylate is used to add one or more vinyls to the backbone of the pre-polymer to form an acrylated pre-polymer. In various embodiments, acrylated pre-polymers are co-polymerized with one or more acrylated co-polymers.Type: GrantFiled: March 23, 2012Date of Patent: April 8, 2014Assignee: Massachusetts Institute of TechnologyInventors: Christopher J. Bettinger, Joost P. Bruggeman, Lino Da Silva Ferreira, Jeffrey M. Karp, Robert S. Langer, Christiaan Nijst, Andreas Zumbuehl, Jason Burdick, Sonia J. Kim
-
Patent number: 8679523Abstract: The present invention comprises methods and compositions for delivery devices. More particularly, the present invention comprises methods and compositions for devices comprising a matrix comprising a polymer network and a non-gellable polysaccharide having oxygen and optionally active agents incorporated therein. The matrix may be formed into any desired shape for treatment of compromised tissue or for delivery of oxygen to a localized environment.Type: GrantFiled: December 29, 2000Date of Patent: March 25, 2014Assignee: Kimberly-Clark Worldwide, Inc.Inventors: Bruce L. Gibbins, Lance D. Hopman